| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC2121 |
| Trial ID | NCT03967223 |
| Disease | Myxoid Liposarcoma | Synovial Sarcoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Letetresgene autoleucel|GSK3377794|Lete-cel |
| HLA | HLA-A*02:01|HLA-A*02:05|HLA-A*02:06 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) |
| Year | 2019 |
| Country | United States |
| Company sponsor | GlaxoSmithKline |
| Other ID(s) | 208467 |
| Cohort1: untreated advanced SS or MRCLS | |||||||||
|
|||||||||
| Cohort2: advanced SS or MRCLS post anthracycline chemo | |||||||||
|
|||||||||